Pharmakologische Endokrinologie

  • Freimut A. Leidenberger

Zusammenfassung

Unter den Sexualsteroiden unterscheidet man bekanntlich nach ihren Hauptwirkungen Östrogene von Androgenen und progesteronähnlichen Substanzen (Gestagenen). Das im geschlechtsreifen Alter der Frau biologisch aktivste Östrogen ist das 17β-Östradiol, das natürliche Gestagen ist das Progesteron, das Hauptandrogen beim Mann Testosteron. Letzteres muß allerdings in vielen Zielorganen in Dihydrotestosteron, das an den androgensensiblen Zellen eigentlich wirksame Androgen, umgewandelt werden. An vielen Zielorganen (z. B. an der Haut und am äußeren Genitale) ist diese Umwandlung Voraussetzung für die androgene Wirkung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Asch RH, Fernandez EO, Siler-Khodr TM et al. (1980) Mechanism of induction of luteal phase defects by danazol. Am J Obstet Gynecol 136: 932PubMedGoogle Scholar
  2. Barbieri R, Ryan KJ (1985) Medical therapy for endometriosis: Endocrine pharmacology. In: Sem Reprod Endocrinol 3: 339CrossRefGoogle Scholar
  3. Bartosik D (1985) Immunologic aspects of endometriosis. Sem-Reprod Endocrinol 3: 329CrossRefGoogle Scholar
  4. Baulieu EE (1985) RU 486: An antiprogestin steroid with contragestive activity in women. In: Beaulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, p 1CrossRefGoogle Scholar
  5. Belghmi K, Michel F, Nicolas JC et al. (1984) Inhibition of enzymes involved in steroid and prostanoid metabolism by steroid used in endometriosis therapy. In: Raynand JP (eds) Medical management of endometriosis. Raven, New York, p 91Google Scholar
  6. Bentley PJ (1980) The endocrinology and pharmacology of reproduction. In: Bentley PJ (eds) Endocrine pharmacology. Cambridge Univ Press, Cambridge, p 270Google Scholar
  7. Bohnet HG, Hanker JP, Schweppe KW, Schneider HPG (1981) Changes of prolactin secretion following long term danazol application. Fertil Steril 25: 728Google Scholar
  8. Braun P, Leyendecker G (1981) The effect of danazol on LH episodes, basal LH and FSH serum levels, estradiol induced positive feedback and LH-RH induced gonadotropin release in the follicular phase of the menstrual cycle. Acta Endocrinol [Suppl] 243: 190AGoogle Scholar
  9. Breckenridge AM, Back DJ, Orme M (1989) Effect of disease and drug interactions on the response to oral contraceptive steroids. In: Michael F (eds) Safety requirements for contraceptive steroids. Cambridge Univ. Press, Cambridge, p 348Google Scholar
  10. Briggs MH, Briggs M (1971) Effect of oral ethinyl estradiol on serum proteins in normal women. Contraception 3: 381CrossRefGoogle Scholar
  11. Briggs MH, Briggs M (1985) Pharmacology of hormonal contraceptives. In Shearman RP (eds) Clinical reproductive endocrinology. Churchill Livingston, Edinburgh, p 656Google Scholar
  12. Clark JH, Peck EJ Jr, Anderson JN (1974) Oestrogen receptors and antagonism of steroid hormone action. Nature 251: 446PubMedCrossRefGoogle Scholar
  13. Dmowski WP, Headley S, Radwanka E (1983) Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normal cycling women. Fertil Steril 39: 49PubMedGoogle Scholar
  14. Edgren RA (1980) Progestagens. In: Clinical use of sex steroids. Yearbook Medical, Chicago, p 1Google Scholar
  15. Elias AN, Gwinup G (1980) Effects of some clinically encountered drugs on steroid synthesis and degradation. Metabolism 29: 582PubMedCrossRefGoogle Scholar
  16. Franchimont P, Cramilion C (1977) The effect of danazol on anterior pituitary function. Fertil Steril 28: 814PubMedGoogle Scholar
  17. Fraser IS (1983) Post danazol amenorrhea. Clin Reprod Fertil 2: 229PubMedGoogle Scholar
  18. Gravanis A, Schaison G, George M, De Brux J, Satyaswaroop PG, Baulieu EE, Robel P (1985) Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 60: 156PubMedCrossRefGoogle Scholar
  19. Gurpide E (1983) Antiestrogenic actions of progesterone and-progestins in women. In: Bardin CE et al. (eds) Progesterone and progestins. Raven, New York, p 149Google Scholar
  20. Hammerstein J (1979) In: Hammerstein J et al. (eds) Androgenisierungserscheinungen bei der Frau. Excerpta Medica, Amsterdam, p 298Google Scholar
  21. Haspels AA (1985) Interruption of early pregnancy by an antiprogestational compound RU 486. Eur J Obstet Gynecol Reprod Biol 20: 169PubMedCrossRefGoogle Scholar
  22. Healy DL (1985) Clinical status of antiprogesterone steroids. Clin Reprod Fertil 3: 277PubMedGoogle Scholar
  23. Healy DL, Chrousos GP, Schulte HM, Williams RF, Gold PW, Baulieu E, Hodgen GD (1983) Pituitary and adrenal responses to the antiprogesterone and antiglucocorticoid steroid RU 486 in primates. J Clin Endocrinol Metab 57: 863PubMedCrossRefGoogle Scholar
  24. Herrmann WL, Schindler HM, Wyss R, Bischof P (1985) Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. In: Baulieu EE, Segal SJ (eds) The antiprogesterone steroid RU 486 and human fertility control. Plenum, New York, p 179CrossRefGoogle Scholar
  25. Johansson EDB (1971) Depression of the progesterone levels in women treated with synthetic gestagens after ovulation. Acta Endocrinol (Copenh) 68: 779Google Scholar
  26. Keller PJ (1986) Chemie und Pharmakologie der synthetischen-Gestagene. In: Kontrazeptive Gestagene. Thieme, Stuttgart, S3Google Scholar
  27. Kopera H (1988) Vortragsmanuskript Fortbildungsseminar für Endokrinologie und Reproduktionsmedizin, HamburgGoogle Scholar
  28. Kovacs L, Sas M, Resch BA, Ugocsai G, Swahn ML, Bygdeman M, Rowe PJ (1984) Termination of very early pregnancy by RU 486 — an antiprogestational compound. Contraception 29: 399PubMedCrossRefGoogle Scholar
  29. Kuhl H (1987) Progestagene zur Empfängnisverhütung. Dtsch Med Wochensch 18/19: 433Google Scholar
  30. Kuhl H, Taubert HD (1987) Das Klimakterium. Pathophysiologic — Klinik Therapie. Thieme, StuttgartGoogle Scholar
  31. Lauersen NG, Wilson KH (1977) Evaluation of danazol as an oral contraceptive. Obstet Gynecol 50: 91PubMedGoogle Scholar
  32. Lauritzen Ch (1987) Hormonale Kontrazeption. Med wiss Buchreihe, Schering AG, Adam Pharma, Essen, S 60Google Scholar
  33. Leyendecker G, Wildt L (1984) Pulsatile Therapie der hypothalamischen Amenorrhoe mit Gonadotropin releasing Hormon. Dtsch med Wochenschr 109: 462PubMedCrossRefGoogle Scholar
  34. Moguilewsky M, Philibert D (1984) RU 38486: Potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J Steroid Biochem 20: 271PubMedCrossRefGoogle Scholar
  35. Nilsson B, Sodergaard R, Damber MG et al. (1983) Free testosterone levels during danazol therapy. Fertil Steril 39: 505PubMedGoogle Scholar
  36. Nicholson RE, Griffiths K (1980) The biochemistry of tamoxifen action. In: Thomas JA et al. (eds) Advances in sex hormone research, vol 4. Urban & Schwarzenberg, München, p 119Google Scholar
  37. Ottosson UB, Nilsson B, Södergaard R, von Schoultz B (1985) Effects of progesterone, progestogens and danazol on the specific Cortisol binding in human plasma. Fertil Steril 43: 856PubMedGoogle Scholar
  38. Reimers DU (1973) Rifampicin and ovulation inhibitors. Sixtyfourth meeting of the professional society of lung and bronchial specialists. Berlin, February, 19Google Scholar
  39. Reyniak KV, Gurpide E (1982) Effect of danazol on gonadal steroidogenesis in patients with a complete form of testicular feminization. Am J Obstet Gynecol 142: 479PubMedGoogle Scholar
  40. Runnebaum R, Rabe T (1987) New progestogens in oral contraceptives. Am J Obstet Gynecol 157: 1059PubMedGoogle Scholar
  41. Schweppe KW (1988) Medikamentöse Behandlung der Endometriose. Gynäkologe 21: 52PubMedGoogle Scholar
  42. Schweppe KW, Assmann G (1984) Changes of plasma lipids and lipoprotein levels during danazol treatment for endometriosis. Horm Metab Res 16: 593PubMedCrossRefGoogle Scholar
  43. Taubert HD, Kuhl H (1981) Kontrazeption mit Hormonen. Thieme, Stuttgart, S 76Google Scholar
  44. Teichmann AT, Wieland H, Brockerhoff P (1989) Sexualhormone, Arteriosklerose und Fettstoffwechsel der Frau. Wiss Verlagsbuchhandlung, StuttgartGoogle Scholar
  45. Vickery BH, Nestor JJ Jr (1987) LH-RH analogs: Development and mechanism of actions. Sem Reprod Endocrinol 5: 353CrossRefGoogle Scholar
  46. Victor A, Weiner E, Johansson EDB (1976) Sex hormone binding globulin: The carrier protein for d-norgestrel. J Clin Endocrinol 43: 244CrossRefGoogle Scholar
  47. Waibel-Treber S, Minne HW, Scharia SH, Bremen TH, Ziegler R, Leyendecker G (1989) Reversible bone loss in women treated with GnRH agonist for endometriosis and uterine leiomyomas. Hum Reprod 4: 384PubMedGoogle Scholar
  48. Wentz AC, Sapp KC (1978) Danazol as a luteolytic agent. Fertil Steril 29: 23PubMedGoogle Scholar
  49. Wright F, Giacomini M, Riati M, Mowszowicz I (1983) Antihormone activity of progesterone and progestins. In: Bardin CW et al (eds) Progesterone and progestins. Raven, New York, p 121Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Freimut A. Leidenberger
    • 1
  1. 1.Institut für Hormon- und FortpflanzungsforschungHamburg 50Deutschland

Personalised recommendations